Results 101 to 110 of about 4,153 (212)

Diabetes Mellitus in Kidney Transplant Recipients and New Hypoglycemic Agent Options [PDF]

Diabetes mellitus (DM) is frequent in kidney transplant recipients (KTRs), reducing graft and patient survival. In recent years, hypoglycemic agents have been approved for chronic kidney disease (CKD) patients, such as sodium glucose co-transporter type ...
Bartoli G., Dello Strologo A., Grandaliano G., Pesce F.   +3 more
core   +1 more source

Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings

Quality in Sport
Introduction: Chronic kidney disease (CKD) is a common, often late-diagnosed and progressive condition associated with increased morbidity and mortality, mainly due to elevated cardiovascular risk. Diabetes is the one of the leading causes of CKD.
Cezary Kubuj, Grzegorz Adaśko, Michał Świda, Jakub Bazarewicz, Urszula Mazur, Marcin Siwik, Daniel Dmowski, Anna Michalska, Paulina Ogonowska, Julia Waszak   +9 more
doaj   +1 more source

Finerenone Ameliorates High Glucose-Induced Podocytes Epithelial-Mesenchymal Transition Through the Regulation of Krüppel-Like Factor 5 in Diabetic Nephropathy

Diabetes, Metabolic Syndrome and Obesity
Jianqiang Shu,1 Dandan Chen,1 Wenzhen Chen,2 Xinyu Zhang,1 Simeng Wang,1 Nannan Chong,3 Zhikang Sun,3 Qinglian Wang,3 Jingshu Sun,4 Ying Xu1 1Department of Nephrology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, People’s Republic ...
Shu J, Chen D, Chen W, Zhang X, Wang S, Chong N, Sun Z, Wang Q, Sun J, Xu Y   +9 more
doaj  

Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis

Diabetology & Metabolic Syndrome
Objective To assess the effects of finerenone and glucagon-like peptide 1 receptor agonists (GLP1-RA) on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), and the relative cardiovascular benefits in patients with or ...
Xia Gu, Shimin Jiang, Yue Yang, Wenge Li
doaj   +1 more source

Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective

BMJ Public Health
Introduction One in three patients with type 2 diabetes (T2D) suffers from any stage of chronic kidney disease (CKD), a chronic illness associated with a high global burden that impacts not only the healthcare system but also societal costs.
Maarten J Postma, Stephan J L Bakker, Sara Wilhelmien Quist, Jeanni van Loon, Michal Pochopién, Jeroen Paulissen   +5 more
doaj   +1 more source

The role of finerenone in heart failure

Trends in Cardiovascular Medicine
Heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) represents approximately half of all HF cases, yet therapeutic options are limited. Mineralocorticoid receptor (MR) overactivation by aldosterone has long been recognized as a key driver of vascular inflammation, cardiac fibrosis, and cardiac hypertrophy ...
Hassan Ismahel, Kieran F. Docherty
openaire   +2 more sources

Finerenone: a game changer for chronic kidney disease patients with type 2 diabetes

Journal of the Pakistan Medical Association
Dear Editor, Type 2 diabetes or (T2D) is characterized by the elevated blood glucose levels resulting from impaired beta-cell function and insulin resistance.
Fizzah Ikram Ul Haq, Aaitain Ikram Ul Haq   +1 more
doaj   +1 more source

Prespecified Analysis of FINEARTS-HF [PDF]

Publisher Copyright: © 2025 The AuthorsBackground: Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin-angiotensin-aldosterone cascade, and mineralocorticoid receptor antagonists may be more ...
Bauersachs, Johann, Butt, Jawad H., Claggett, Brian L., Desai, Akshay S., Fonseca, Cândida, Henderson, Alasdair D., Jhund, Pardeep S., Kosiborod, Mikhail N., Lage, Andrea, Lam, Carolyn S.P., Lay-Flurrie, James, Linssen, Gerard C.M., McMurray, John J.V., Petrie, Mark C., Pitt, Bertram, Scheerer, Markus F., Schou, Morten, Senni, Michele, Shah, Sanjiv J., Solomon, Scott D., Vaduganathan, Muthiah, Verma, Subodh, Viswanathan, Prabhakar, Voors, Adriaan A., Zannad, Faiez   +24 more
core   +2 more sources

Focus on finerenone: the FINEARTS-HF study

European Heart Journal Supplements
Abstract Mineralcorticoid receptor (MR) blockade is a mainstay of treatment for heart failure with reduced ejection fraction (HFrEF); however, the benefit is less well established in heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).
Tolone, Stefano, Tinti, Maria Denitza, Pulignano, Giovanni, Natale, Enrico, Gabrielli, Domenico   +4 more
openaire   +2 more sources

In Reply to ‘Finerenone: Fiddling With Hyperkalemia?’ [PDF]

American Journal of Kidney Diseases, 2021
Vikas S, Sridhar, Hongyan, Liu, David Z I, Cherney   +2 more
openaire   +2 more sources